TY  - JOUR
A1  - Bellut, Maximilian
A1  - Raimondi, Anthony T.
A1  - Haarmann, Axel
A1  - Zimmermann, Lena
A1  - Stoll, Guido
A1  - Schuhmann, Michael K.
T1  - NLRP3 inhibition reduces rt-PA induced endothelial dysfunction under ischemic conditions
JF  - Biomedicines
N2  - Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is a mainstay of acute ischemic stroke treatment but is associated with bleeding complications, especially after prolonged large vessel occlusion. Recently, inhibition of the NLRP3 inflammasome led to preserved blood–brain barrier (BBB) integrity in experimental stroke in vivo. To further address the potential of NLRP3 inflammasome inhibition as adjunct stroke treatment we used immortalized brain derived endothelial cells (bEnd5) as an in vitro model of the BBB. We treated bEnd5 with rt-PA in combination with the NLRP3 specific inhibitor MCC950 or vehicle under normoxic as well as ischemic (OGD) conditions. We found that rt-PA exerted a cytotoxic effect on bEnd5 cells under OGD confirming that rt-PA is harmful to the BBB. This detrimental effect could be significantly reduced by MCC950 treatment. Moreover, under ischemic conditions, the Cell Index — a sensible indicator for a patent BBB — and the protein expression of Zonula occludens 1 stabilized after MCC950 treatment. At the same time, the extent of endothelial cell death and NLRP3 expression decreased. In conclusion, NLRP3 inhibition can protect the BBB from rt-PA-induced damage and thereby potentially increase the narrow time window for safe thrombolysis in stroke.
KW  - NLRP3
KW  - inflammasome
KW  - MCC950
KW  - rt-PA
KW  - blood–brain barrier
KW  - Cell Index
KW  - ASC
KW  - ischemic stroke
KW  - i.v. thrombolysis
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-267261
SN  - 2227-9059
VL  - 10
IS  - 4
ER  -